Skip to content

Abstinence debate finds more consensus than difference

Initiating HAART with any one of four 3 x 5 drug choices leads to longest survival in San Francisco

Two-year data continue to show promise for T-20

Once daily Reverset safe and effective over ten days in treatment-naïve and –experienced patients

Tenofovir has viral potency, a good lipid and safety profile, and should be available for first line HAART says study

Efavirenz can be used at normal dose with rifampicin, Thais report

WHO: we are still on track for 3 x 5 HIV treatment goal

Taking HAART not associated with sexual risk taking, but belief that HAART makes HIV less infectious is, finds meta-analysis

Azithromycin resistant syphilis found in HIV-positive gay men